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Table 1. (Continued )
n 5 46
Cy/SD TBI 18 (39)
Flu/Bu 2 (4)
Flu/Bu/Thymo 6 (13)
fTBI/Cy 5 (11)
Other 3 (7)
GVHD prophylaxis (%)
FK +/2 MTX +/2 MMF 40 (87)
CSA +/2 MTX +/2 MMF 6 (13)
Corticosteroid dose administered (%)
< 1 mg/kg/day 2 (4)
$ 1 mg/kg/day - <2 mg/kg/day x $ 3
days
18 (39)
$ 2 mg/kg/day x $ 3 days 26 (56.5)
Organ involvement of GVHD (%)
Skin 27 (59)
GI 32 (70)
Liver 20 (43.5)
Multi-organ 33 (72)
Daclizumab doses administered (%)
5 33 (72)
4 5 (11)
3 3 (6.5)
# 2 5 (11)
Poster Session II S355of patients may be preferentially responsive to daclizumab. Addi-
tional analysis is ongoing assessing the impact of daclizumab on liver
GVHD.562
MANAGEMENT STRATEGIES FOR ALLOGENEIC HEMATOPOETIC STEM
CELL TRANSPLANT (HSCT) GRAFT VERUS HOST DISEASE (GVHD) PRO-
PHYLAXIS IN THE SETTING OF CALCINEURIN INHIBITOR (CNI) TOXICITY
Harnicar, S.1, Mathew, S.1, Adel, N.1, Giralt, S.2, Jakubowski, A.2 1Me-
morial Sloan-Kettering Cancer Center, New York, NY; 2Memorial
Sloan-Kettering Cancer Center, New York, NY
Background: Calcineurin inhibitors have become the standard of
care for the prophylaxis of acute graft versus host disease, however
both cyclosporine and tacrolimus can cause adverse effects. While
many of these adverse reactions are dose dependent, others may re-
quire alternate prophylaxis therapy. Strategies can be performed to
minimize CNI toxicity: target lower CNI serum levels, change to an-
other CNI, change to a steroid based regimen, or change to a siroli-
mus and/or mycophenolate (MMF) regimen. The current study
sought to evaluate the incidence of GVHD as well as survival in
a group of patients who were unable to continue therapeutic calci-
neurin inhibitor prophylaxis.
Methods: Allogeneic HSCT patients $ 18 years of age who
received cyclosporine or tacrolimus based GVHD prophylaxis
from Jan. 2007 through May 2010 at Memorial Sloan-Kettering
Cancer Center were examined in this retrospective analysis.Table 1. Calcineurin Inhibitor Changes and GVHD
Development/Death
CNI CHANGES N 5 35
GVHD,
N (%)
GRADE III-IV
GVHD, N (%)
GVHD
DEATHS,
N (%)
MEDIAN
DAY TO GVHD
DEATH
LOW TARGET
BASED
6 2 (33) 1 (17) 1 (17) 79
CNI CHANGE 12 6 (50) 2 (17) 2 (17) 280
STEROID BASED 6 2 (33) 0 (0) 1 (17) 245
SIROLIMUS/MMF
BASED
11 6 (55) 3 (27) 4 (36) 91Patients were required to have a change in their prophylaxis regi-
men by one of the strategies previously listed prior to day +100.
Low target CNI was defined as # 5 ng/mL for tacrolimus and #
200 ng /mL for cyclosporine. CNIs must have been used for pro-
phylaxis and not treatment of GVHD. Patients were excluded if
they did not engraft or developed GVHD after day +110. Patient
information was obtained from the pharmacy database and elec-
tronic medical records. Data included demographics, oncologic di-
agnosis, type of transplant, conditioning regimen, GVHD
prophylaxis regimen, and day to GVHD development and death.
Reason for death was verified by use of the Copelan Criteria and
assessed through Aug. 2010.
Results:Out of a possible 293 patients identifed, 35 patients met the
inclusion criteria. Seventeen underwent HSCT for a leukemia diag-
nosis and 18 either had lymphoma or another hematologic neoplastic
disorder. Fifty-one percent (18/35) of patients received a tacrolimus
based regimen and 49% (17/35) received cyclosporine initially. The
majority of CNI prophylactic regimen changes were due to acute re-
nal failure (63%). As illustrated in Table 1, the incidence of GVHD
for the four alternative prophylaxis strategies ranged from 33-55%.
Deaths attributable to GVHD were most frequent in the Siroli-
mus/MMF arm (36%) and occurred before day +100.
Conclusion: Outcomes in this limited patient population suggest
caution with the use of sirolimus or MMF as an alternative GVHD
prophylaxis regimen early post transplant for patients with CNI tox-
icity.563
INFECTIOUS COMPLICATIONS ASSOCIATED WITH THE USE OF ANTITHY-
MOCYTE GLOBULIN IN REDUCED INTENSITY ALLOGENEIC TRANS-
PLANTS
Loth, K.1, Naik, S.2, Kennedy, L.A.1, Levitan, D.2, Zamkoff, K.2,
Hurd, D.2 1Wake Forest University Baptist Medical Center, Winston-
Salem, NC; 2Wake Forest University Baptist Medical Center, Winston-
Salem, NC
Introduction Rationale for ATG: Reduced intensity conditioning
(RIC) allogeneic (allo) regimens frequently use antithymocyte glob-
ulin (ATG) for graft versus host disease (GVHD) prevention espe-
cially in unrelated donor (URD) stem cell transplants (SCT) and
mismatched related (mMRD) donor transplants where risk of
GVHD is thought to occur at higher frequency. Use of ATG is fre-
quently associated with infectious complications outweighing bene-
fit of GVHD prevention.
Patients: We retrospectively analyzed 42 patients who underwent
RIC allo SCT between January 2001 and December 2009. Addi-
tionally, we have transplanted 20 RIC allo SCT patients from Jan-
uary 2010 to October 2010 for whom we will have mature data to
report. The mean age was 58 years and majority of male patients
with M:F ratio of 14:7 compared to 16:5 in the ATG versus non
ATG group. All of the patients receiving regimens without ATG
received a MRD allo SCT with the majority (. 90%) of patients
receiving ATG received URD allo SCT. Two patients (9.5%) re-
ceived ATG in view of mismatched related donor transplants. Dis-
ease states requiring SCT with ATG was AML 61.9%, MDS 19%,
NHL 9.5% and SCT without ATG was AML 47.6%, MDS
28.6%, CML 9.5%.
Results:The overall rate of infection in patients who received ATG
was around 90% versus 62%. Bacterial infections were the most
documented infection (61.9% vs 52.4%) and 14.2% of patients had
documented fungal infections in each group. Forty three percent
of patients receiving ATG developed viral infections (n 5 9) versus
19% in those not receiving ATG (n5 4). Documented fungal infec-
tions were the same between both groups (n 5 3, 14.2%). Docu-
mented viral infections were more in the ATG group (28.5% vs
19%). During the engraftment period there were more infections
in patients who received ATG versus those that did not, 14.2% vs
4.8%. Acute GVHD was more prevalent in the ATG group
(23.8% vs 14.3%) and chronic GHVD was greater in the non
ATG group (28.6% vs 14.3%).
Conclusion: There is a greater incidence of infections, primarily
bacterial and viral, in patients treated with ATG versus those that
are not. More studies need to be conducted to determine the
Patients (N542) ATG (n521) No ATG (n521)
Mean Age, years 56.6 59.3
Male 66.6% (n514) 76.2% (n516)
Disease Type
-CLL 0 4.8% (n51)
-CML 0 9.5% (n52)
-MDS 19% (n54) 28.6% (n56)
-AML 61.9% (n513) 47.6% (n510)
-APL 4.8% (n51) 0
-Multiple Myeloma 0 4.8% (n51)
-NHL 9.5% (n52) 4.8% (n51)
-ALL 4.8% (n51) 0
Donor Type
-MRD 0 100%
-URD 90.5% 0
-mMRD 9.5% 0
Primary Outcome
Overall Infection 90.4% (n519) 61.9% (n513)
No infection 28.6% (n52) 80% (n58)
-Positive Bacterial Cultures 61.9% (n513) 52.4% (n511)
-Positive Fungal Cultures 14.2% (n53) 14.2% (n53)
-Positive Viral Cultures 28.5% (n56) 19% (n54)
—CMV (n) 4 4
—EBV (n) 1 0
—EBV & BK (n) 1 0
Probable Infection 23.8% (n55) 9.5% (n52)
—Radiographic only 2 2
—CMV/EBV PCR only 3 0
Secondary Outcomes
Bacterial Infection 14.2% (n53) 4.8% (n51)
Fungal Infection 0 0
Viral Infection 0 0
Acute GVHD 23.8% (n55) 14.3% (n53)
-Grade 1 2 2
-Grade 2 1 1
-Grade 3 2 0
-Grade 4 0 0
Chronic GVHD 14.3% (n53) 28.6% (n56)
-Grade 1 2 4
-Grade 2 1 1
-Grade 3 0 1
-Grade 4 0 0
Survival at 1 year 33.3% (n57) 47.6% (n510)
Disease free at 1 year 23.8% (n55) 38.1% (n58)
S356 Poster Session IIsignificance of these infections and the role for anti-infective prophy-
laxis or the possibility of minimizing immunosuppression due to the
absence of high grade GVHD in both groups.564
EVALUATION OF A PHARMACY CHECKLIST DURING BLOOD AND MAR-
ROW TRANSPLANT ADMISSION
Gray, L.J.L.1, Raymond, C.1, Szwajcer, D.2,3, Hink, J.1, Graumann, A.1,
Ali, M.1, Seftel, M.D.2,3 1Winnipeg Regional Health Authority,
Winnipeg, MB, Canada; 2University of Manitoba, Winnipeg, MB,
Canada; 3CancerCare Manitoba, Winnipeg, MB, Canada
Background: Clinical pharmacist review is an important opportu-
nity for quality control in the blood and marrow transplant (BMT)
process. The Manitoba BMT program developed a formalized pro-
cess for this review in the form of an admission checklist that is
completed by a BMT pharmacist. The checklist documents phar-
macist review of all relevant components of the transplant regimen.
Included is verification of chemotherapy regimen, prophylaxis for
graft versus host disease, infectious diseases, and tumor lysis. Other
verifications include antiemetic regimen, growth factors, intrathe-
cal therapy, cell infusion orders, and medication reconciliation.The need for dose adjustments based on organ function is also in-
cluded.
Methods: The checklists of 32 consecutive adult patients admitted
to the transplant ward were audited. The purpose of the audit was
to assess checklist completion by a BMT pharmacist.
Results: All patients (100%) had a checklist attached to their phar-
macy profile. In 15% (n 5 5) of patients, there was no verification
that the transplant regimen was the same as the planned regimen
written in the primary transplant physician comprehensive trans-
plant workup package. Verification of MUGA results in 28%
(n 5 9) of patients and an intrathecal therapy plan in 15% (n 5 5)
was not documented. Confirmation of medication reconciliation
was present in 72% (n5 23) of admissions. The presence of a patient
summary by an outpatient pharmacist prior to admission was docu-
mented in only 72% (n 5 23) of admissions.
There were no reported ‘‘near misses’’ or critical events related to
the admission orders. 82% of pharmacy checklist sheets had at least
one explanatory note written on the checklist.
Conclusions: The use of a checklist at time of BMT admission has
helpeddevelop a consistent and thoroughreview, thuspreventingmed-
ication errors and omissions. The checklist is a useful tool for training
new staff and education purposes. It is being explored as a communica-
tion tool between inpatient and outpatient pharmacists. It has evolved
to includepatient specific explanatory comments, thus adopting a com-
munication role in addition to being a process documentation tool.
This also prevents repeat questions posed to prescribers. This process
has identified quality improvement opportunities in the areas of hand-
over fromoutpatient to inpatient pharmacy and in the standardized or-
der sets and admission paperwork.TRANSPLANT NURSING-ADMINISTRATION
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RECOGNIZING THE IMPORTANCE OF A WORK CULTURE COMMITTEE
AND ITS LONG TERM POSITIVE EFFECTS
Frith, J., Sito, E. Duke University Health System, Durham, NC
Work culture can be defined as,’’ a combination of qualities in an
organization and its employees that arise from what is generally re-
garded as appropriate ways to think and act.’’ (Rollins and Roberts,
1998). These qualities and behaviors are often ‘‘passed down’’ from
employee to employee based on what a group assumes works well
within a particular environment, and is therefore deemed ‘‘the cor-
rect way’’. This is especially true in the healthcare setting. It is for
this reason aWork Culture Committee was recognized as a necessity
for our unit. This committee was created as ameans to assess the per-
ceptions and satisfaction of ALL employees workingwithin a specific
environment.i.e. the entire Adult Bone Marrow Transplant
(ABMT) program. This committee is nurse driven and comprised
of representatives from various aspects of the ABMT team including
RN’s, unit clerks, nursing assistants, care extenders (NP and PA) and
various staff from the outpatient clinic setting. The goal is to im-
prove teamwork, communication, and staff recognition within the
program, thereby increasing performance and satisfaction within
the work environment. It is our hope that this will lead to greater em-
ployee retention as well as increased patient satisfaction and safety.
Prior to the first meeting, the committee surveyed ALL staff using
an employee satisfaction survey tool. The data was then reviewed
and used to create short and long term realistic goals for the pro-
gram. It was then decided that the committee needed to meet
monthly and include various representatives from all staff groups
as stated above. The committee has only been active for 8 months,
but several short term goals have already been met. These include
improved communication between charge RN’s and unit clerks to
work together regarding on and off the unit for better flow. A report
system has been established between the staff RN’s and nursing as-
sistants including daily safety rounds and expectations. A staff recog-
nition board was created on the unit in response to the survey as
a way to acknowledge staff for a job well done and boost teammoral.
This committee has many aspiring long term goals and hopes to mo-
tivate ALL staff tomake a positive investment in themselves and their
workplace.
